Accessibility Menu
Cue Biopharma logo

Cue Biopharma

(NASDAQ) CUE

Current Price$25.30
Market Cap$107.28M
Since IPO (2018)-93%
5 Year-94%
1 Year+7%
1 Month+24%

Cue Biopharma Financials at a Glance

Market Cap

$107.28M

Revenue (TTM)

$32.73M

Net Income (TTM)

-$19.52M

EPS (TTM)

-$5.53

P/E Ratio

-4.62

Dividend

$0.00

Beta (Volatility)

1.47 (Average)

Price

$25.30

Volume

82,634

Open

$25.76

Previous Close

$25.39

Daily Range

$24.60 - $26.75

52-Week Range

$4.97 - $41.42

Estimated Earnings Date

Aug 18, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cue Biopharma

Industry

Biotechnology

Employees

29

CEO

Usman Azam, MD

Headquarters

Boston, MA 02139, US

CUE Financials

Key Financial Metrics (TTM)

Gross Margin

99.76%

Operating Margin

-59.83%

Net Income Margin

-59.65%

Return on Equity

-98.30%

Return on Capital

-86.59%

Return on Assets

-63.23%

Earnings Yield

-21.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$107.28M

Shares Outstanding

4.20M

Volume

82.63K

Avg. Volume

747.26K

Financials (TTM)

Gross Profit

$32.65M

Operating Income

-$19.58M

EBITDA

-$15.84M

Operating Cash Flow

-$24.46M

Capital Expenditure

-$148.00K

Free Cash Flow

-$24.61M

Cash & ST Invst.

$16.38M

Total Debt

$3.44M

Cue Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.69M

+1250.6%

Gross Profit

$5.69M

+1250.6%

Gross Margin

100.00%

N/A

Market Cap

$107.28M

N/A

Market Cap/Employee

$2.62M

N/A

Employees

41

N/A

Net Income

-$5.18M

+57.8%

EBITDA

-$4.25M

+62.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$16.38M

+24.7%

Total Debt

$3.44M

-51.7%

Accounts Receivable

$7.25M

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.88M

+967.0%

Short Term Debt

$1.56M

-77.5%

Return on Assets

-63.23%

N/A

Return on Invested Capital

-83.39%

N/A

Free Cash Flow

-$11.06M

-32.9%

Operating Cash Flow

-$10.94M

-33.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$3.05+3.39%
SPRBSpruce Biosciences, Inc.
$55.11+4.43%
OTLKOutlook Therapeutics, Inc.
$1.71+6.21%
NRXPNRx Pharmaceuticals, Inc.
$3.73+4.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$153.23+0.00%
ONDSOndas
$7.83+0.02%
KEELKeel Infrastructure
$6.03+0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.67+0.04%

Questions About CUE

What is the current price of Cue Biopharma?

Cue Biopharma is trading at $25.39 per share.

What is the 52-week range for Cue Biopharma?

Over the past 52 weeks, Cue Biopharma has traded between $4.97 and $41.42.

How much debt does Cue Biopharma have?

As of the most recent reporting period, Cue Biopharma reported total debt of $3.44M.

How much cash does Cue Biopharma have on hand?

Cue Biopharma reported $16.38M in cash and cash equivalents in its most recent financial results.

What is Cue Biopharma’s dividend yield?

Cue Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.